Evidence map›Paper›PMID 38264355›Full record

ArticleFrontiers in cell and developmental biology2023

Radiomics signatures for predicting the Ki-67 level and HER-2 status based on bone metastasis from primary breast cancer.

Hongxiao Zhang, Shuxian Niu, Huanhuan Chen, Lihua Wang, Xiaoyu Wang, Yujiao Wu, Jiaxin Shi, Zhuoning Li, Yanjun Hu, Zhiguang Yang and 1 more

Abstract read
In one paragraph

Article in Frontiers in cell and developmental biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hongxiao Zhang *School of Intelligent Medicine, China Medical University, Shenyang, Liaoning, China.
Shuxian Niu *School of Intelligent Medicine, China Medical University, Shenyang, Liaoning, China.
Huanhuan Chen *Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Lihua WangDepartment of Radiology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China.
Xiaoyu WangDepartment of Radiology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China.
Yujiao WuSchool of Intelligent Medicine, China Medical University, Shenyang, Liaoning, China.
Jiaxin ShiSchool of Intelligent Medicine, China Medical University, Shenyang, Liaoning, China.
Zhuoning LiSchool of Intelligent Medicine, China Medical University, Shenyang, Liaoning, China.
Yanjun HuDepartment of Medical Imaging, Cancer Hospital of China Medical University, Liaoning Cancer Hospital and Institute, Shenyang, Liaoning, China.
Zhiguang YangDepartment of Radiology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, China.
Xiran JiangSchool of Intelligent Medicine, China Medical University, Shenyang, Liaoning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This study explores the potential of radiomics to predict the proliferation marker protein Ki-67 levels and human epidermal growth factor receptor 2 (HER-2) status based on MRI images of patients with spinal metastasis from primary breast cancer. A total of 110 patients with pathologically confirmed spinal metastases from primary breast cancer were enrolled between Dec. 2017 and Dec. 2021. All patients underwent T1-weighted contrast-enhanced MRI scans. The PyRadiomics package was used to extract features from the MRI images based on the intraclass correlation coefficient and least absolute shrinkage and selection operator. The most predictive features were used to develop the radiomics signature. The Chi-Square test, Fisher's exact test, Student's

Indexed as

breast cancerHER-2Ki-67radiomicsspinal metastasis

Identifiers

PMID38264355
PMCPMC10804450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.